AstraZeneca has bought an exclusive global licence to develop and market RXC006, a porcupine inhibitor for fibrotic diseases including idiopathic pulmonary fibrosis (IPF). Redx will receive up to ...

Join your peers and key opinion leaders in person and take away critical insights at the only dedicated IPF meeting. Already confirmed attendees include Boehringer Ingelheim, Genentech ...